Source comparison
KPV Side Effects Long Term Research — Comparison Across Study Durations
12 weeks (human) Human subjects with UC 500mcg–2mg daily oral Zero discontinuations due to AE; mild GI discomfort in 8% of subjects Symptom questionnaires, endoscopic inflammation scoring, basic metabolic panel Strongest human evidence but insufficient for lon
This comparison does not assign a generated winner or score.
- 12 weeks (human)
- Human subjects with UC
- 500mcg–2mg daily oral
- Zero discontinuations due to AE; mild GI discomfort in 8% of subjects
- Symptom questionnaires, endoscopic inflammation scoring, basic metabolic panel
- Strongest human evidence but insufficient for long-term extrapolation
- 16 weeks (rodent)
- C57BL/6 mice
- Equivalent to 15mg/kg human dose
- No hepatotoxicity, nephrotoxicity, or haematologic changes
- Comprehensive metabolic panel, histopathology, immune cell counts
- Well-controlled but species differences limit human applicability
- 24 weeks (rodent)
- Wistar rats
- 5–20mg/kg
- Transient leukocytosis at week 18 (resolved by week 22) without infection
- Weekly CBC, bi-weekly organ histology, wound healing assays
- Longest published trial; detected reversible immune marker shift
- 52 weeks (theoretical)
- No published data
- N/A
- Unknown
- This duration has never been studied in any species
- The comparison underscores a critical constraint: even the longest KPV studies represent fractions of the timeframes required to detect outcomes like cancer risk (typically 5–10 years latency), endocrine disruption (months to years for HPA axis adaptation), or cumulative organ stress. Researchers working with compounds like Cerebrolysin face identical evidence gaps. Robust short-term data paired with absent multi-year human trials.